Be the signal

Log In | Sign Up



Hikma Pharmaceuticals

Selected Articles

2025-07-31
GlobeNewswire
Asthma Treatment Market to Hit USD 36.36 Billion by 2032, Driven by Biologic Adoption and Technological Advancements in Inhalers | SNS Insider
Read More
2025-07-23
GlobeNewswire
Africa Pharmaceuticals Market Analysis, Growth Trends, and Forecast Report 2025-2032 | Urbanization and NCDs Drive Demand, Regulatory Harmonization & Local Production Boost Growth
Read More
2025-07-23
GlobeNewswire
8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth
Read More
2025-06-30
Yahoo Entertainment
FTSE 100 LIVE: Markets higher as US-UK trade deal comes into force
Read More
2025-06-27
IPWatchdog.com
Other Barks and Bites for Friday, June 27: EGC Says 'NERO CHAMPAGNE' Unduly Exploits Protected Designation of Origin; SCOTUS Seeks SG Views on Skinny Label Issues in Hikma; and a Big Week for Copyrights and AI
Read More
2025-06-27
GlobeNewswire
Immunomodulator Therapeutics Global Market Research 2024-2030 | Investment in R&D Fuels Next-Gen Immunomodulator Therapies Amid Rising Autoimmune Cases
Read More
2025-06-17
GlobeNewswire
Antibiotic Collaboration and Licensing Agreements Analysis Report and Directory 2016-2025: Benchmark Deals Entered Into by the World's Leading Biopharma Companies
Read More
2025-06-11
ETF Daily News
Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?
Read More
2025-06-06
GlobeNewswire
Peripheral Neuropathy Treatment Market Landscape 2025-2029: Robust Drug Pipeline to Expand the Market by $481 Million
Read More
2025-06-06
GlobeNewswire
Anesthesia Drugs Market Set to Reach USD 8.6 Billion by 2032, Amid Rising Surgical Demand and Advancements in Anesthetics – SNS Insider
Read More

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom. GB00B0LCW083 www.hikma.com